Product Details
Forxiga
Dapagliflozin10 mg
Tablet
DIN/PIN/NPN
02435470
Manufacturer
AstraZeneca
Formulary Listing Date
2016-11-30
Unit Price
2.7300
Amount MOH Pays
0.6825
Coverage Status
General Benefit Chronic-Use Medication Insulin or Oral Hypoglycemic Product
ODB Formulary Therapeutic Classification
Therapeutic Note
Dapagliflozin 10 mg Tablet: Added on to metformin for patients: - Who have inadequate glycemic control on metformin and - Who have a contraindication or intolerance to a sulfonylurea or - For whom insulin is not an option. Added on to a sulfonylurea for patients: - Who have inadequate glycemic control on a sulfonylurea and - Who have a contraindication or intolerance to metformin or - For whom insulin is not an option. For the treatment of adult patients with New York Heart Association (NYHA) class II and III heart failure, as an adjunct to standard of care therapy, for the treatment of heart failure with reduced ejection fraction (HFrEF) [Left ventricular ejection fraction (LVEF less than or equal to 40%)]. Standard of care therapies include beta-blockers, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), plus a mineralocorticoid receptor antagonist.
ATC Code
A10BK01
Interchangeable Products
DIN/ PIN/ NPN | Brand name | Unit Price | Amount MOH pays |
---|---|---|---|
02435470 | Forxiga | 2.7300 | 0.6825 |
02527197 | Apo-Dapagliflozin | 0.6825 | 0.6825 |
02531410 | Auro-Dapagliflozin | 0.6825 | 0.6825 |
02519860 | GLN-Dapagliflozin | 0.6825 | 0.6825 |
02531372 | Jamp Dapagliflozin | 0.6825 | 0.6825 |
02535300 | M-Dapagliflozin | 0.6825 | 0.6825 |
02531569 | PMS-Dapagliflozin | 0.6825 | 0.6825 |
02518740 | Sandoz Dapagliflozin | 0.6825 | 0.6825 |
02538342 | NRA-Dapagliflozin | 0.6825 | 0.6825 |